Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
14,465 total articles
United Therapeutics (UTHR) is trading off recent highs but sits squarely in front of multiple regulatory catalysts — an FDA decision window for ralinepag and a late-April 2027 decision for nebulized Tyvaso in IPF. The balance sheet, free cash flow of $1.093B, and attractive profitability metrics provide a foundation for upside should approvals come…
QuinStreet delivered a materially stronger print in Q4 2026 and guided to a $1.45-$1.55B revenue range for fiscal 2027. At roughly $14.50 and a market cap near $827M, the stock trades at single-digit EV/sales and a low-teens EV/EBITDA on recent free cash flow performance. The setup is a classic growth + value mismatch: fundamental momentum plus an …
Viking Therapeutics' VK2735 posted strong 21-week weight-loss and maintenance data showing 16-19% body-weight reductions and up to 97% maintenance with flexible dosing. The stock has already rerated; this trade idea lays out an entry at $40.33, stop at $33.00 and a $65.00 target over a 180 trading-day horizon, with catalysts, valuation framing and …
<p>MP Materials is executing the industrial pivot investors wanted - moving from low-value concentrate to separated NdPr oxide, metal sales and magnet-making. That is producing striking revenue growth. The problem for buyers today is valuation: much of the positive narrative appears priced into the stock, and operational costs tied to downstream ra…
Meta's Muse rollout and early partner integrations create a credible pathway for the company to become the default transactional layer across consumer web services. The stock has run, but fundamentals and cash flow support taking a structured long position as Muse transitions from product-launch headlines to recurring revenue.
Microsoft sits at the intersection of enterprise cloud, productivity software and AI infrastructure. At ~$499, the stock offers a mix of steady cash generation (free cash flow $66.99B), attractive profitability (ROE 30.23%) and clear AI upside. This trade idea outlines a long entry at $499.00, a $540.00 target and a $475.00 stop loss on a long-term…
Roche's Phase II results for enicepatide and the initiation of Zealand's Phase III ZUPREME program for petrelintide (in partnership with Roche) signal the company is transitioning from latecomer to credible competitor in GLP-1/dual-agonist obesity therapeutics. With a $356B market cap, a reasonable P/E of 22.8, and existing diabetes/diagnostics inf…
Sandisk's large buyback (reported at $15.5 billion, potentially retiring up to 5.6% of its float) creates a liquidity and supply shock in the memory/storage complex. That dynamic favors Western Digital through tighter industry capacity, pricing leverage, and renewed investor appetite for well-capitalized HDD incumbents. We lay out a mid-term (45 tr…
Mirion (MIR) trades near $16.35 after a summer low and presents a disciplined long opportunity. The business benefits from secular growth in nuclear power and medical radiation detection, recent revenue acceleration, and a healthy cash position. Valuation is rich versus earnings but reasonable on a cash-adjusted basis. We lay out exact entry, stop …
SiTime is positioned to convert AI-driven datacenter demand into revenue and margin expansion. Recent beats and a strategic Renesas timing acquisition set up a clear growth runway — but the stock is already richly valued and execution risk is real. This trade targets capture of a mid-term re-rate with disciplined risk control.
Achieve Life Sciences (ACHV) remains a binary clinical-stage name tied to the commercial potential of cytisinicline. Recent financing and elevated short interest compress the near-term risk/reward. We downgrade the rating to Hold but recommend a tactical long on a controlled dip: entry $7.50, stop $6.50, target $9.25 over a mid-term 45 trading day …
Corning is the backbone supplier for optical connectivity in the AI data-center buildout. Recent contract wins and a material capacity expansion plan make the stock a buy after the selloff tied to a $2B ATM program. Valuation is rich, but free cash flow generation and a dominant position in fiber and connectivity tilt the risk/reward in favor of di…
D-Wave (QBTS) has rallied into event-driven interest but fundamentals and valuation leave limited room for complacency. This trade idea recommends taking profits on longs and initiating a tactical short on a bounce to $18.92, targeting a gap-fill move toward $16.00 over the next 45 trading days, while keeping a tight stop at $19.60. The setup balan…
Kronos Worldwide has reported improving TiO2 volumes and expanding gross margins alongside a move to lower-cost inventory and restructuring savings. If tightness in feedstock markets (sulfur/sulfate-route inputs) persists, Kronos' recent operational gains and cash conversion (free cash flow $66.5M) support a tradeable long. This idea lays out entry…
Nebius (NBIS) is executing pricing power and capacity expansion at a moment when AI infrastructure demand is still accelerating. Recent moves - a material GPU price increase and guidance that points to a multi-billion dollar revenue runway - improve 2027 earnings optionality. This trade idea lays out a disciplined long entry at $235 with a $299.86 …
<p>Compass Therapeutics (CMPX) is trading near its 52-week low after a headline clinical miss, but the stock shows extreme technical oversoldness, a large short base, and two upcoming scientific touchpoints that could reprice the shares if data or tone improves. This is a speculative, time-limited trade: buy a small position at $1.17 with a $0.90 s…
B2Gold just cleared a key regulatory hurdle for its Fekola Regional assets in Mali and reported strong 2025 production and $3 billion revenue. At roughly $7.1B market cap and a PE near 9.2, the stock looks cheap enough that a disciplined buyback program or steady production gains could push the shares higher. Elevated all-in sustaining costs, safet…
Roblox is a market-leading creator platform sitting on a $35B market cap, negative earnings today but generating meaningful free cash flow. If AI unlocks faster content creation, discovery and monetization, the company can reframe itself from a games platform to a persistent entertainment layer. This trade sets an entry near the current price, a di…
Nebius' latest price increase forces a simple investor math: can the company convert higher per-unit pricing into enough volume and margin expansion to justify a $7.8 billion market cap? This trade idea proposes a disciplined, mid-term long on a measured pullback, with clear entry, stop and target, while flagging the execution and demand risks that…
Ternium (TX) currently trades at roughly $55.88 with a $10.95B market cap, a P/E of 15.9 and a semi-annual distribution of $1.30. If management materially reduces CapEx and converts a portion of incremental free cash flow to dividends, the company could plausibly lift payouts toward a 7% yield. This trade buys that scenario at current levels with a…
Quest Diagnostics (DGX) is trading near multi-month highs on robust growth in physician, hospital and consumer channels and a fast-growing advanced diagnostics portfolio. Reimbursement uncertainty from Medicare creates headline risk, but a $25.9B market cap, solid cash flow profile, and double-digit growth in higher-margin tests make a mid-term lon…
Lufax trades near $1.16, roughly 0.09x reported book value, creating a high-risk, high-reward long opportunity for disciplined traders. The trade hinges on resolution or clarification of past disclosure issues, stabilization in credit losses, and a re-rating from investors who have forced the stock to overshoot on the downside.
Intel is no longer just a laggard catching up. Recent product wins, process progress and improving momentum have shifted the risk-reward profile. This trade idea outlines a long position with specific entry, stop and target, timing across a 180-trading-day horizon, and a balanced view of catalysts and risks.
China Automotive Systems (CAAS) is upgraded to Buy after the company began volume shipments of electric power steering systems to a major European automaker and trades at a sub-0.4 PB and ~3.6 PE. The setup is actionable for a mid-term swing, but the small float and choppy daily volume call for disciplined sizing, limit orders, and a strict stop.
Meta appears to have established a meaningful lead in foundational AI and product-integrated models. This trade targets an asymmetric upside as the market re-rates Meta for sustainable higher monetization per user across ads, commerce, and new AI-driven services. Entry $380.00, target $480.00, stop $330.00 — long term (180 trading days).
